Investor Alert

Market Pulse Archives

July 9, 2020, 7:27 a.m. EDT

Poseida Therapeutics to raise up to $236 million in planned IPO

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Poseida Therapeutics Inc. (PSTX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane


Poseida Therapeutics Inc. /zigman2/quotes/205712311/composite PSTX -3.37% said Thursday it will offer 14 million share in its initial public offering, priced at $16 each, up from an earlier plan to offer 10 million share priced at $14 to $16 each. The company expects to raise $204.8 million after expenses, or about $236 million if the underwriters exercise the option to buy another 2.1 million shares. BofA Securities, Piper Sandler and William Blair are underwriting the deal. The company has applied to list on Nasdaq, under the ticker "PSTX." Proceeds of the deal will be used to fund clinical trials and for working capital and other general corporate purposes. "We are a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure," the company says in its prospectus. The company had a net loss of $28.8 million in the first three months of 2020, after a loss of $13.3 million in the year-earlier period.

US : U.S.: Nasdaq
$ 9.18
-0.32 -3.37%
Volume: 153,918
Sept. 24, 2020 4:00p
P/E Ratio
Dividend Yield
Market Cap
$587.29 million
Rev. per Employee

Get news alerts on Poseida Therapeutics Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.